Spinal Muscular Atrophy Outcome Measures Workshop (English Language)

Published: 09 May 2024

Earlier this year, NMD4C, MDC and Quebec SMA Network hosted the first interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal Muscular Atrophy (SMA).

To complement this training session, the NMD4C will be hosting an English-language interactive training workshop on standardizing assessment practices in SMA outcome measures.

This workshop will be taking place the day before the Allied Professionals Forum in Montreal.

Please ensure you register before the deadline of June 18th, 2024.

Please ensure that you meet the eligibility criteria:

  • Must be a physiotherapist or occupational therapist at a Canadian institution/clinic evaluating patients of any age with SMA.
  • Must be a NMD4C member.

Disclaimer:

We have a limited number of seats available for this workshop (in-person only). Participants will be selected based on considerations related to geography, case load and clinic needs. There is a discounted hotel room rate as part of the Allied Professionals Forum meeting and financial support for travel and accommodations will be provided (details to follow upon acceptance).

Register Here!

Spinal muscular atrophy outcome measures training registration open for December 3rd event.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.